EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
Recruiting · NCT05723107 · Interventional (participants receive a specific treatment) · Lead sponsor: NYU Langone Health
View the official record on ClinicalTrials.gov →Interventions studied
ChemotherapyEndoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)
What this trial is about
This is a single arm study in the treatment of pancreatic ductal adenocarcinoma (PDAC). The investigators propose to test the tolerability of chemotherapy plus endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) using the RF Electrode in patients receiving palliative second or third line therapy for unresectable non-metastatic pancreatic cancer.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Diagnosed and histologically confirmed PDAC by biopsy
- Axial CT scan or MRI consistent with PDAC with at least 1 cm in greatest diameter
- ECOG performance status 0-2
- Patients with locally advanced PDAC, who have not responded or progressed on first line chemotherapy, are deemed not resectable based on multidisciplinary review, and show no evidence of distant metastasis
- Lesions between 1 - 4cm in size
Exclusion criteria
- Patients that show evidence of distant metastasis
- Endoscopically non-accessible mass
- Pregnant patients
- Inability to provide informed consent
- Lesions \<1cm, or \>4cm in greatest diameter
Where it is running
1 location listed across 1 US state.
- Tisch Hospital - New York, New York, United States